Relmada Therapeutics (RLMD) said Friday initial results from a phase 2 trial of NDV-01 for bladder cancer were positive.
The study, which was presented at the annual meeting of the American Urology Association, showed that 90% of patients achieved high-grade disease-free status after treatment, supporting NDV-01's potential as a new therapy for non-muscle invasive bladder cancer, the company said.
At the three-month mark, 85% of patients responded to treatment, and all patients with carcinoma in situ showed a complete response, it added.
At six months, all seven patients who were evaluated remained disease-free, including one who needed a second treatment at three months, according to the company.
The drug was generally safe and well-tolerated, with only mild side effects like urinary urgency and slight pain, which resolved within a day, Relmada said.
Shares of the company were down over 41% in recent trading.
Price: 0.38, Change: -0.27, Percent Change: -41.30
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.